Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006
Bertrand Favier
Breast Cancer Research and Treatment, 2011
View PDFchevron_right
Economic burden associated with breast cancer recurrence
David Nathanson, Suzanne Havstad
Cancer, 2006
View PDFchevron_right
The economic burden of metastatic breast cancer: A systematic review of literature from developed countries
Risha Gidwani
Cancer Treatment Reviews, 2011
View PDFchevron_right
The costs of breast cancer prior to and following diagnosis
Marie-rose Christiaens
European Journal of Health Economics, 2011
View PDFchevron_right
COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB IN THE TREATMENT OF METASTATIC BREAST CANCER
International Journal of Pharmacy and Pharmaceutical Sciences (IJPPS)
International Journal of Pharmacy and Pharmaceutical Sciences, 2015
View PDFchevron_right
Projecting the Prevalence and Costs of Metastatic Breast Cancer From 2015 through 2030
Anagha Gogate
JNCI Cancer Spectrum
View PDFchevron_right
Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients
Erin ROMAN
BMJ Open, 2020
View PDFchevron_right
Direct medical and non-medical costs of a one-year care pathway for early breast cancer: results of a French multicenter prospective study
Alix Combes
2019
View PDFchevron_right
Cost of Illness Associated with Metastatic Breast Cancer
Daniel Gilden
Breast Cancer Research and Treatment, 2004
View PDFchevron_right
Development of a model to predict the cost of treatment of breast cancer with chemotherapy at Groote Schuur hospital
Nyasha Guzha
2017
View PDFchevron_right
Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype
Filipa Fontes
ESMO open, 2020
View PDFchevron_right
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
Andrea Manca, Alastair Gray
European Journal of Cancer, 2011
View PDFchevron_right
Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK
Anita Burrell
PharmacoEconomics, 2001
View PDFchevron_right
Cost of breast cancer based on real-world data: a cancer registry study in Italy
Stefano Capri
View PDFchevron_right
Influence of surgical and treatment choices on the cost of breast cancer care
Joseph Gardiner
The European Journal of Health Economics, 2003
View PDFchevron_right
Health system costs for stage-specific breast cancer: a population-based approach
Refik Saskin
View PDFchevron_right
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
Montserrat Vera
BMC Cancer, 2011
View PDFchevron_right
Cost-Effectiveness of Intensive Vs. Standard Follow-Up Models for Patients with Breast Cancer in Shiraz, Iran
nahid hatam
Asian Pacific journal of cancer prevention : APJCP, 2016
View PDFchevron_right
Economic Evaluation of Breast Cancer Treatment: Considering the Value of Patient Choice
Wa the one
Journal of Clinical Oncology, 2003
View PDFchevron_right
The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States
Travis Wang
Advances in Therapy, 2021
View PDFchevron_right
Evaluating Trastuzumab and Lapatinib’s Economic Impact in the Treatment of Metastatic Breast Cancer in Veneto Region Cohort
Daniele Chiffi
View PDFchevron_right
Cost-Effectiveness Analysis of Trastuzumab Emtansine in the Treatment of Metastatic Breast Cancer
Cid Vianna
International Journal of Pharmacy and Pharmaceutical Sciences
View PDFchevron_right
A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer
Robert Launois
PharmacoEconomics, 1996
View PDFchevron_right
Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes
Gerardus Frederix
Value in Health, 2012
View PDFchevron_right
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Jean-marc Ferrero
European journal of cancer (Oxford, England : 1990), 2018
View PDFchevron_right
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
maryam ghiasipour
Cancer, 2007
View PDFchevron_right
Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer
G. van der Wilt
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2005
View PDFchevron_right
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy
Susan Brunskill
Health technology assessment (Winchester, England)
View PDFchevron_right
The economic burden of metastatic breast cancer in Spain
Edit Remak
European Journal of Hospital Pharmacy, 2018
View PDFchevron_right
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: A UK perspective considering long-term toxicity and pattern of recurrence.
Christopher McCabe
View PDFchevron_right
Indirect costs in patients with breast cancer: protocol for a systematic review
Reza Jahangiri
2020
View PDFchevron_right
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States
Alberto Montero
Breast cancer research and treatment, 2016
View PDFchevron_right
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial
Vassilis Fragoulakis
Annals of Oncology, 2008
View PDFchevron_right